You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Medtronic
Harvard Business School
Merck
Moodys

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ARN-509


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ARN-509?

ARN-509 is an investigational drug.

There have been 38 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2020.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are Janssen Scientific Affairs, LLC, Aragon Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are forty US patents protecting this investigational drug and five hundred and two international patents.

Recent Clinical Trials for ARN-509
TitleSponsorPhase
Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate CancerNational Cancer Institute (NCI)Phase 2
Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate CancerOregon Health and Science UniversityPhase 2
Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate CancerOHSU Knight Cancer InstitutePhase 2

See all ARN-509 clinical trials

Clinical Trial Summary for ARN-509

Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509

See all ARN-509 clinical trials

US Patents for ARN-509

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ARN-509   Start Trial Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
ARN-509   Start Trial Androgen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
ARN-509   Start Trial Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.